ClinicalTrials.gg
CompletedNCT01327547Updated Dec 6, 2017Results posted

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

A Phase 4 interventional study of Maraviroc and Placebo in HIV Coinfection, sponsored by ViiV Healthcare. Completed at 48 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-06.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.

Enrollment
10th of 44
138 · median 36
Started
2011
with 2 others
Phase 4
15 of 44
none open now
Registered
34th of 44
by date
Lead sponsor
8 of 44
ViiV Healthcare

Among the 44 studies testing maraviroc in HIV Infections, this one is the 10th largest by enrollment, is one of 3 that started in 2011, is one of 15 in phase 4, and was the 34th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About maraviroc

Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing maraviroc in HIV Infections as a file.
02

Study summary

To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.

03

Conditions studied

  • HIV Coinfection

Keywords

  • HIV coinfection
  • maraviroc
  • CCR5 blocker
  • entry inhibitor
  • liver disease
  • viral hepatitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • coinfected with and/or .
  • Undetectable HIV-1 RNA for at least 3 months prior to the screening visit
  • Treatment with current antiretroviral therapy (3-6 drugs excluding low-dose ritonavir) for at least 5 months.

Exclusion criteria

Exclusion Criteria:

  • Currently receiving maraviroc.
  • Active opportunistic infections.
  • and/or AST >5x .
  • Direct >1.5x upper limit of normal.
  • Severe or decompensated liver disease.
  • Liver disease unrelated to viral hepatitis infection.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    1.0

    Drug: Maraviroc

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • 150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy

    Also known as: Selzentry, Celsentri

  • DrugPlacebo

    150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48

    Percentage of participants with Grade 3 or Grade 4 ALT abnormalities defined as \>5x upper limit of normal (ULN) for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, up to and including Week 48 in the maraviroc arm versus the placebo arm. The baseline was defined as the last measurement prior to Day 1 dosing.

    Time frame: 48 weeks

Secondary outcomes

  1. Percentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Through Week 144

    Percentage of participants with Grade 3 or Grade 4 ALT abnormalities defined as \>5x upper limit of normal (ULN) for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, up to and including Week 96 and Week 144 in the maraviroc arm versus the placebo arm. The baseline was defined as the last measurement prior to Day 1 dosing.

    Time frame: Week 96 and 144

  2. Time to Development of Grade 3 and Grade 4 ALT Abnormalities

    Time taken in days to development of Grade 3 and Grade 4 ALT abnormalities defined as \>5x ULN for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, at Week 144.

    Time frame: 144 weeks

  3. Percentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Associated With a Change From Baseline ALT >100 IU/L

    Percentage of participants who had Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT \>100 IU/L during the 144-week period. Baseline will be defined as the last measurement prior to Day 1 dosing.

    Time frame: 144 weeks

  4. Time to Development of Grade 3 and Grade 4 ALT Abnormalities at Week 144 Associated With a Change From Baseline ALT >100 IU/L

    Time to development of Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT \>100 IU/L during the 144-week period. Baseline will be defined as the last measurement prior to Day 1 dosing.

    Time frame: 144 weeks

  5. Number of Participants With Hy's Law Abnormalities Through Week 144

    Hy's law was defined as a total bilirubin \>2x ULN with a simultaneous ALT or aspartate transaminase (AST)\>3x ULN, excluding participants with an alkaline phosphatase\>3x ULN

    Time frame: 144 weeks

  6. Percentage of Participants With Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Concentration <40 Copies/mL at Week 48, 96 and 144

    The Food and Drug Administration (FDA's) snapshot algorithm was used to derive the efficacy endpoint of the proportion of participants with HIV-1 RNA \<40 copies/mL at Week 48. This algorithm included the missing data imputation method and used the plasma HIV-1 RNA concentration in the visit window only, followed the "virology-first principle" and considered a participant who had a missing plasma HIV-1 RNA concentration, or switched to a prohibited background anti-retroviral regimen or discontinues from the study or study drug as a failure (MSDF).

    Time frame: Week 48, 96 and 144

  7. Mean Change From Baseline in CD4+ and CD8+ Cell Counts at Week 48, 96 and 144

    Immunologic response (magnitude of change in CD4+ and CD8+ cell counts from baseline) was measured. Baseline value for CD4 and CD8 is defined as the pre-dose measurement taken at Day 1 visit.

    Time frame: Week 48, 96 and 144

  8. Mean Change From Baseline in CD38 Expression on CD4 and CD8 Cells at Weeks 48, 96 and 144

    Plasma samples were used to determine markers of immune activation namely CD38 expression on CD4 and CD8 cells.

    Time frame: 48, 96 and 144 weeks

  9. Mean Change From Baseline in Markers of Immune Activation: C-reactive Protein (CRP) - Week 48, 96 and 144.

    Plasma samples were used to determine markers of immune activation namely CRP.

    Time frame: 48, 96 and 144 weeks

  10. Mean Change From Baseline in Markers of Immune Activation: D Dimer - Week 48, 96 and 144

    Plasma samples were used to determine markers of immune activation namely D-Dimer.

    Time frame: 48, 96 and 144 weeks

  11. Mean Change From Baseline in Markers of Immune Activation: Transforming Growth Factor-beta (TGF Beta) - Week 48, 96 and 144

    Plasma samples were used to determine markers of immune activation namely TGF beta.

    Time frame: 48, 96 and 144 weeks

  12. Mean Change From Baseline in Log10 Plasma Hepatitis C Virus (HCV) RNA at Week 48, 96 and 144

    Plasma samples were used to determine HCV RNA using the Roche COBAS Ampliprep/COBAS HCV Taqman assay, RUO version (LOD=15 IU/mL).Baseline value for HCV RNA/HBV DNA is defined as the pre-dose measurement taken at Day 1 visit.

    Time frame: 48, 96 and 144 weeks

  13. Mean Change From Baseline in Plasma Hepatitis B Virus (HBV) DNA at Week 48, 96 and 144

    Plasma samples were used to determine HBV DNA using the Roche COBAS Taqman HBV assay. Baseline value for HCV RNA/HBV DNA is defined as the pre-dose measurement taken at Day 1 visit.

    Time frame: 48, 96 and 144 weeks

  14. Mean Change From Baseline in Enhanced Liver Fibrosis (ELF) Test at Week 48, 96 and 144

    The markers of fibrosis assessed in this test comprised hyaluronic acid (CHA), tissue inhibitor of metalloproteinase (CTIMP1) and procollagen III N-terminal peptide (CP3NP); these are components of the extracellular matrix and basement sinusoidal membrane of the liver and are elevated during activation of the stellate cell. The ELF tests were performed on an ADVIA Centaur XP and the composite score was calculated as follows: ELF score = 2.278 + 0.851 ln(CHA) + 0.751 ln (CP3NP) + 0.394 ln(CTIMP1). ELF score \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.

    Time frame: 48, 96 and 144 weeks

  15. Mean Change From Baseline in the Hepatic Elastography (FibroscanTM) at Week 48, 96 and 144

    Participants had transient hepatic elastography using FibroScan technology. It rapidly and non invasively measures hepatic tissue stiffness. Through a probe, a low frequency vibration of low amplitude is transmitted to the liver. The velocity of the wave that is generated during the procedure correlates directly with tissue stiffness as it passes through the liver; the harder or stiffer the liver, the faster the shear wave propagates. Results are reported in kilopascals (kPa). A negative change in the fibroscan values (i.e. decrease in liver stiffness) correlates with a decrease in fibrosis and thus improved outcome.

    Time frame: 48, 96 and 144 weeks

  16. Absolute Fibrosis Score (Ishak) in Liver Biopsy Samples at Baseline and at Week 144

    Samples were processed and sent to a central reader for scoring for fibrosis and other analyses such as Sirius red and α smooth muscle actin staining for activated stellate cells. Samples were collected, processed, stored and shipped in accordance with the procedure documented in a separate handling document. The Ishak fibrosis scoring system was used to score the fibrosis observed, with a minimum score of 0 and maximum score of 6 (where 0 = no fibrosis, 1 = expansion of some portal areas with or without septa, 2 = expansion of most portal areas with or without septa, 3 = expansion of most portal areas with occasional portal or portal bridging, 4 = expansion of portal areas with marked bridging \[portal-portal and/or portal-central\], 5 = marked bridging with occasional nodules \[incomplete cirrhosis\], 6 = cirrhosis, probable or definitive). The scores for liver biopsies were summarized based upon the availability of liver biopsy results.

    Time frame: Baseline and Week 144

  17. Change From Baseline in Fibrosis Score (Ishak) in Liver Biopsy Samples at Week 144

    Samples were processed and sent to a central reader for scoring for fibrosis and other analyses such as Sirius red and α smooth muscle actin staining for activated stellate cells. Samples were collected, processed, stored and shipped in accordance with the procedure documented in a separate handling document. The Ishak fibrosis scoring system was used to score the fibrosis observed, with a minimum score of 0 and maximum score of 6 (where 0 = no fibrosis, 1 = expansion of some portal areas with or without septa, 2 = expansion of most portal areas with or without septa, 3 = expansion of most portal areas with occasional portal or portal bridging, 4 = expansion of portal areas with marked bridging \[portal-portal and/or portal-central\], 5 = marked bridging with occasional nodules \[incomplete cirrhosis\], 6 = cirrhosis, probable or definitive). The scores for liver biopsies were summarized based upon the availability of liver biopsy results.

    Time frame: Week 144

  18. Percentage of Participants Who Were Hospitalized Due to Hepatic Disease Through Week 144

    Healthcare resource utilization data was collected using the Healthcare Resource Utilization Questionnaire at all study visits except Screening and Baseline. Other components of healthcare resource utilization, including length of hospital stay, type of ward, associated investigative and therapeutic procedures and concomitant medications were captured from primary and secondary data sources.

    Time frame: 144 Weeks

  19. Summary of Estimated Maraviroc PK Parameters

    Week 4 and Week 48 clinic visits were scheduled such that a trough sample may be taken within a time window of 8-16 hours after the previous dose (Ctrough). Blood samples (4mL) were collected from all participants at the Week 4 and 48 visits.

    Time frame: Week 48

  20. Exposure-response Relationship Between Change From Baseline in Liver Fibrosis Biomarkers Versus MVC Cavg at Week 48

    The relationship between change from baseline in liver fibrosis biomarkers (AST, ALT, ALK, BIL, ELF and FSCN) versus MVC Cavg was analyzed using Bayesian methods. P-values were assessed for significance in the relationship between liver fibrosis biomarkers and MVC Cavg. P-value \<0.05 was regarded as significantly related.

    Time frame: Week 48

07

Results

Posted Nov 14, 2014
Limitations and caveats
The median time to development of Grade 3 and 4 ALT abnormalities was not estimable due to too few events reported under each treatment group.

Participant flow

In this study, 138 participants were randomized, of which 137 participants received the study drug. Participants were randomized at 37 sites in 9 countries. Five sites received drug and screened subjects but did not randomize any subjects; 2 sites received drug but did not screen any subjects.

Participant flow — Overall Study
MilestoneMaravirocPlacebo
Started7067
Randomized and not treated01
Completed5045
Not completed2022
Withdrew: Adverse event41
Withdrew: Death12
Withdrew: Lost to follow-up66
Withdrew: Non-compliance with study treatment02
Withdrew: Withdrawal by subject37
Withdrew: Does not meet entrance criteria22
Withdrew: Protocol violation10
Withdrew: Non-compliance due to alcohol intake01
Withdrew: Required prohibited medication20
Withdrew: Non-compliance with study procedures10
Withdrew: By investigator in subject's interest01

Outcome measures

PrimaryPercentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48

Percentage of participants with Grade 3 or Grade 4 ALT abnormalities defined as \>5x upper limit of normal (ULN) for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, up to and including Week 48 in the maraviroc arm versus the placebo arm. The baseline was defined as the last measurement prior to Day 1 dosing.

Time frame:
48 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48
Percentage of participantsMaravirocPlacebo
Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 481.41.5
Statistical analysis
  • Maraviroc vs Placebo · Cochran-Mantel-Haenszel · p = 0.4598 · Difference in proportion: -0.0020 · 95% CI -0.0417 to 0.0376Difference in proportion: CMH approach weighted by hepatitis B virus (HBV) status and usage of protease inhibitor (PI) regimen strata was used to calculate the statistics.
SecondaryPercentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Through Week 144

Percentage of participants with Grade 3 or Grade 4 ALT abnormalities defined as \>5x upper limit of normal (ULN) for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, up to and including Week 96 and Week 144 in the maraviroc arm versus the placebo arm. The baseline was defined as the last measurement prior to Day 1 dosing.

Time frame:
Week 96 and 144
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Through Week 144
Percentage of participantsMaravirocPlacebo
at Week 961.43.0
at Week 1442.94.5
Statistical analysis
  • Maraviroc vs Placebo · Mean difference (final values): -0.0167 · 95% CI -0.0653 to 0.0319CMH approach weighted by HBV status and usage of PI regiment strata, is used to calculate the statistics. The point estimate and 95% CI are difference in proportions between MVC and placebo for the participants meeting secondary endpoint.
  • Maraviroc vs Placebo · Mean difference (final values): -0.0177 · 95% CI -0.0805 to 0.0452CMH approach weighted by HBV status and usage of PI regiment strata, is used to calculate the statistics. The point estimate and 95% CI are difference in proportions between maraviroc and placebo for the participants meeting secondary endpoint.
SecondaryTime to Development of Grade 3 and Grade 4 ALT Abnormalities

Time taken in days to development of Grade 3 and Grade 4 ALT abnormalities defined as \>5x ULN for participants whose baseline ALT ≤ULN, or \>3.5x baseline for participants whose baseline ALT \>ULN, at Week 144.

Time frame:
144 weeks
Reported as:
Median · Days
Time to Development of Grade 3 and Grade 4 ALT Abnormalities
DaysMaravirocPlacebo
Time to Development of Grade 3 and Grade 4 ALT AbnormalitiesNA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Associated With a Change From Baseline ALT >100 IU/L

Percentage of participants who had Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT \>100 IU/L during the 144-week period. Baseline will be defined as the last measurement prior to Day 1 dosing.

Time frame:
144 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 3 and Grade 4 ALT Abnormalities Associated With a Change From Baseline ALT >100 IU/L
Percentage of participantsMaravirocPlacebo
Grade 32.84.4
Grade 41.40.0
SecondaryTime to Development of Grade 3 and Grade 4 ALT Abnormalities at Week 144 Associated With a Change From Baseline ALT >100 IU/L

Time to development of Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT \>100 IU/L during the 144-week period. Baseline will be defined as the last measurement prior to Day 1 dosing.

Time frame:
144 weeks
Reported as:
Median · Days
Time to Development of Grade 3 and Grade 4 ALT Abnormalities at Week 144 Associated With a Change From Baseline ALT >100 IU/L
DaysMaravirocPlacebo
Time to Development of Grade 3 and Grade 4 ALT Abnormalities at Week 144 Associated With a Change From Baseline ALT >100 IU/LNA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Hy's Law Abnormalities Through Week 144

Hy's law was defined as a total bilirubin \>2x ULN with a simultaneous ALT or aspartate transaminase (AST)\>3x ULN, excluding participants with an alkaline phosphatase\>3x ULN

Time frame:
144 weeks
Reported as:
Number · participants
Number of Participants With Hy's Law Abnormalities Through Week 144
participantsMaravirocPlacebo
Number of Participants With Hy's Law Abnormalities Through Week 14400
SecondaryPercentage of Participants With Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Concentration <40 Copies/mL at Week 48, 96 and 144

The Food and Drug Administration (FDA's) snapshot algorithm was used to derive the efficacy endpoint of the proportion of participants with HIV-1 RNA \<40 copies/mL at Week 48. This algorithm included the missing data imputation method and used the plasma HIV-1 RNA concentration in the visit window only, followed the "virology-first principle" and considered a participant who had a missing plasma HIV-1 RNA concentration, or switched to a prohibited background anti-retroviral regimen or discontinues from the study or study drug as a failure (MSDF).

Time frame:
Week 48, 96 and 144
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Concentration <40 Copies/mL at Week 48, 96 and 144
Percentage of participantsMaravirocPlacebo
Week 4877.179.1
Week 9667.170.1
Week 14458.667.2
Statistical analysis
  • Maraviroc vs Placebo · Difference in proportion: -0.0150 · 95% CI -0.1484 to 0.1185Difference in proportion: CMH approach weighted by HBV status and usage of PI regimen strata was used to calculate the statistics.
  • Maraviroc vs Placebo · Mean difference (final values): -0.0255 · 95% CI -0.1784 to 0.1274Difference in proportion: CMH approach weighted by HBV status and usage of PI regimen strata was used to calculate the statistics.
  • Maraviroc vs Placebo · Mean difference (final values): -0.0830 · 95% CI -0.2421 to 0.0761Difference in proportion: CMH approach weighted by HBV status and usage of PI regimen strata was used to calculate the statistics.
SecondaryMean Change From Baseline in CD4+ and CD8+ Cell Counts at Week 48, 96 and 144

Immunologic response (magnitude of change in CD4+ and CD8+ cell counts from baseline) was measured. Baseline value for CD4 and CD8 is defined as the pre-dose measurement taken at Day 1 visit.

Time frame:
Week 48, 96 and 144
Reported as:
Mean · Cells/µL
Mean Change From Baseline in CD4+ and CD8+ Cell Counts at Week 48, 96 and 144
Cells/µLMaravirocPlacebo
CD4+ (week 48, n=69, 67)3.1 ± 142.5842.0 ± 166.35
CD8+ (week 48, n=69, 67)7.8 ± 229.5328.9 ± 293.18
CD4+ (week 96, n=69, 67)5.1 ± 146.6449.7 ± 177.18
CD8+ (week 96, n=69, 67)-2.7 ± 228.9262.6 ± 376.67
CD4+ (week 144, n=69, 67)17.2 ± 184.8641.7 ± 200.00
CD8+ (week 144, n=69, 67)12.6 ± 293.8244.1 ± 387.61
Statistical analysis
  • Maraviroc vs Placebo · ANCOVA · p = 0.1174 · Difference in least square (ls) mean: -41.12 · 95% CI -92.72 to 10.49Difference in Least Square (LS) Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.5930 · Difference in ls mean: -21.96 · 95% CI -103.05 to 59.12Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.0669 · Difference in ls mean: -48.26 · 95% CI -99.93 to 3.41
  • Maraviroc vs Placebo · ANCOVA · p = 0.1799 · Difference in ls mean: -65.28 · 95% CI -161.07 to 30.50
  • Maraviroc vs Placebo · ANCOVA · p = 0.3859 · Difference in ls mean: -27.71 · 95% CI -90.71 to 35.29
  • Maraviroc vs Placebo · ANCOVA · p = 0.5571 · Difference in ls mean: -31.86 · 95% CI -138.93 to 75.21
SecondaryMean Change From Baseline in CD38 Expression on CD4 and CD8 Cells at Weeks 48, 96 and 144

Plasma samples were used to determine markers of immune activation namely CD38 expression on CD4 and CD8 cells.

Time frame:
48, 96 and 144 weeks
Reported as:
Mean · cell/mm³
Mean Change From Baseline in CD38 Expression on CD4 and CD8 Cells at Weeks 48, 96 and 144
cell/mm³MaravirocPlacebo
Week 48 (n=69, 67)-12.2 ± 129.8243.0 ± 135.71
Week 96 (n=69, 67)5.4 ± 134.6447.4 ± 186.74
Week 144(n=69, 67)23.4 ± 169.5050.7 ± 219.95
Statistical analysis
  • Maraviroc vs Placebo · ANCOVA · p = 0.0153 · Difference in ls mean: -56.06 · 95% CI -101.20 to -10.92Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.0947 · Difference in ls mean: -44.93 · 95% CI -97.72 to 7.87
  • Maraviroc vs Placebo · ANCOVA · p = 0.3595 · Difference in ls mean: -29.75 · 95% CI -93.74 to 34.24
SecondaryMean Change From Baseline in Markers of Immune Activation: C-reactive Protein (CRP) - Week 48, 96 and 144.

Plasma samples were used to determine markers of immune activation namely CRP.

Time frame:
48, 96 and 144 weeks
Reported as:
Mean · mg/dL
Mean Change From Baseline in Markers of Immune Activation: C-reactive Protein (CRP) - Week 48, 96 and 144.
mg/dLMaravirocPlacebo
Week 48 (n=70, 67)0.4 ± 8.183.1 ± 26.66
Week 96 (n=70, 67)0.0 ± 5.16-0.7 ± 3.32
Week 144 (n=70, 67)0.6 ± 7.99-0.3 ± 5.28
Statistical analysis
  • Maraviroc vs Placebo · ANCOVA · p = 0.4476 · Difference in ls mean: -2.53 · 95% CI -9.11 to 4.05Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.3012 · Difference in ls mean: 0.67 · 95% CI -0.61 to 1.96
  • Maraviroc vs Placebo · ANCOVA · p = 0.4196 · Difference in ls mean: 0.92 · 95% CI -1.33 to 3.17
SecondaryMean Change From Baseline in Markers of Immune Activation: D Dimer - Week 48, 96 and 144

Plasma samples were used to determine markers of immune activation namely D-Dimer.

Time frame:
48, 96 and 144 weeks
Reported as:
Mean · ng/dL
Mean Change From Baseline in Markers of Immune Activation: D Dimer - Week 48, 96 and 144
ng/dLMaravirocPlacebo
Week 48 (n= 68, 65)-101.1 ± 753.24-20.4 ± 215.62
Week 96 (n= 68, 65)-88.1 ± 740.14-23.1 ± 201.55
Week 144 (n= 68, 65)-97.4 ± 768.989.8 ± 358.07
Statistical analysis
  • Maraviroc vs Placebo · ANCOVA · p = 0.9904 (Not specifed.) · Difference in ls mean: 0.30 · 95% CI -48.66 to 49.26Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.7697 · Difference in ls mean: 10.87 · 95% CI -62.44 to 84.18Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.5816 · Difference in ls mean: -24.49 · 95% CI -112.21 to 63.23Difference in LS Mean
SecondaryMean Change From Baseline in Markers of Immune Activation: Transforming Growth Factor-beta (TGF Beta) - Week 48, 96 and 144

Plasma samples were used to determine markers of immune activation namely TGF beta.

Time frame:
48, 96 and 144 weeks
Reported as:
Mean · ng/L
Mean Change From Baseline in Markers of Immune Activation: Transforming Growth Factor-beta (TGF Beta) - Week 48, 96 and 144
ng/LMaravirocPlacebo
Week 48 (n= 67, 66)64.1 ± 4857.31-165.0 ± 2584.89
Week 96 (n= 67, 66)-227.5 ± 4417.59-296.5 ± 2200.97
Week 144 (n= 67, 66)792.0 ± 6772.411275.4 ± 5044.79
Statistical analysis
  • Maraviroc vs Placebo · ANCOVA · p = 0.3786 · Difference in ls mean: 498.04 · 95% CI -617.33 to 1613.41Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.4388 · Difference in ls mean: 348.70 · 95% CI -539.61 to 1237.01Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.8559 · Difference in ls mean: -173.57 · 95% CI -2060.81 to 1713.68Difference in LS Mean
SecondaryMean Change From Baseline in Log10 Plasma Hepatitis C Virus (HCV) RNA at Week 48, 96 and 144

Plasma samples were used to determine HCV RNA using the Roche COBAS Ampliprep/COBAS HCV Taqman assay, RUO version (LOD=15 IU/mL).Baseline value for HCV RNA/HBV DNA is defined as the pre-dose measurement taken at Day 1 visit.

Time frame:
48, 96 and 144 weeks
Reported as:
Mean · Log10 values
Mean Change From Baseline in Log10 Plasma Hepatitis C Virus (HCV) RNA at Week 48, 96 and 144
Log10 valuesMaravirocPlacebo
Week 48 (n= 45, 45)-3.2 ± 0.60-3.2 ± 0.68
Week 96 (n= 45, 45)-3.2 ± 0.50-3.4 ± 0.81
Week 144 (n= 45, 45)-3.1 ± 0.57-3.3 ± 0.72
Statistical analysis
  • Maraviroc vs Placebo · ANCOVA · p = 0.8024 · Difference in ls mean: 0.03 · 95% CI -0.22 to 0.28Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.2660 · Difference in ls mean: 0.15 · 95% CI -0.12 to 0.43Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.2855 · Difference in ls mean: 0.15 · 95% CI -0.12 to 0.41Difference in LS mean
SecondaryMean Change From Baseline in Plasma Hepatitis B Virus (HBV) DNA at Week 48, 96 and 144

Plasma samples were used to determine HBV DNA using the Roche COBAS Taqman HBV assay. Baseline value for HCV RNA/HBV DNA is defined as the pre-dose measurement taken at Day 1 visit.

Time frame:
48, 96 and 144 weeks
Reported as:
Mean · Log10 values
Mean Change From Baseline in Plasma Hepatitis B Virus (HBV) DNA at Week 48, 96 and 144
Log10 valuesMaravirocPlacebo
Week 48 (n= 15, 10)-2.6 ± 1.55-3.0 ± 0.11
Week 96 (n= 15, 14)-3.3 ± 0.94-3.0 ± 0.00
Week 144 (n= 15, 15)-3.4 ± 0.96-3.0 ± 0.00
Statistical analysis
  • Maraviroc vs Placebo · ANCOVA · p = 0.7778 · Difference in ls mean: 0.15 · 95% CI -0.93 to 1.23Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.9991 · Difference in ls mean: 0.00 · 95% CI -0.10 to 0.10Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.7275 · Difference in ls mean: -0.02 · 95% CI -0.16 to 0.11Difference in LS Mean
SecondaryMean Change From Baseline in Enhanced Liver Fibrosis (ELF) Test at Week 48, 96 and 144

The markers of fibrosis assessed in this test comprised hyaluronic acid (CHA), tissue inhibitor of metalloproteinase (CTIMP1) and procollagen III N-terminal peptide (CP3NP); these are components of the extracellular matrix and basement sinusoidal membrane of the liver and are elevated during activation of the stellate cell. The ELF tests were performed on an ADVIA Centaur XP and the composite score was calculated as follows: ELF score = 2.278 + 0.851 ln(CHA) + 0.751 ln (CP3NP) + 0.394 ln(CTIMP1). ELF score \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.

Time frame:
48, 96 and 144 weeks
Reported as:
Mean · ELF score
Mean Change From Baseline in Enhanced Liver Fibrosis (ELF) Test at Week 48, 96 and 144
ELF scoreMaravirocPlacebo
Week 48 (n= 70, 67)0.2 ± 0.700.1 ± 0.71
Week 96 (n= 70, 67)0.4 ± 0.730.4 ± 0.58
Week 144 (n= 70, 67)0.4 ± 0.720.4 ± 0.69
Statistical analysis
  • Maraviroc vs Placebo · ANCOVA · p = 0.5201 · Difference in ls mean: 0.07 · 95% CI -0.15 to 0.30Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.4657 · Difference in ls mean: -0.08 · 95% CI -0.28 to 0.13
  • Maraviroc vs Placebo · ANCOVA · p = 0.8087 · Difference in ls mean: -0.03 · 95% CI -0.25 to 0.20Difference in LS Mean
SecondaryMean Change From Baseline in the Hepatic Elastography (FibroscanTM) at Week 48, 96 and 144

Participants had transient hepatic elastography using FibroScan technology. It rapidly and non invasively measures hepatic tissue stiffness. Through a probe, a low frequency vibration of low amplitude is transmitted to the liver. The velocity of the wave that is generated during the procedure correlates directly with tissue stiffness as it passes through the liver; the harder or stiffer the liver, the faster the shear wave propagates. Results are reported in kilopascals (kPa). A negative change in the fibroscan values (i.e. decrease in liver stiffness) correlates with a decrease in fibrosis and thus improved outcome.

Time frame:
48, 96 and 144 weeks
Reported as:
Mean · kPa
Mean Change From Baseline in the Hepatic Elastography (FibroscanTM) at Week 48, 96 and 144
kPaMaravirocPlacebo
Week 48 (n= 25, 28)-1.3 ± 2.410.4 ± 5.71
Week 96 (n= 25, 28)-0.8 ± 2.950.4 ± 5.70
Week 144 (n= 25, 28)-1.7 ± 2.45-0.3 ± 4.39
Statistical analysis
  • Maraviroc vs Placebo · ANCOVA · p = 0.1417 · Difference in ls mean: -1.84 · 95% CI -4.31 to 0.63Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.2679 · Difference in ls mean: -1.44 · 95% CI -4.01 to 1.14Difference in LS Mean
  • Maraviroc vs Placebo · ANCOVA · p = 0.1366 · Difference in ls mean: -1.48 · 95% CI -3.45 to 0.49Difference in LS Mean
SecondaryAbsolute Fibrosis Score (Ishak) in Liver Biopsy Samples at Baseline and at Week 144

Samples were processed and sent to a central reader for scoring for fibrosis and other analyses such as Sirius red and α smooth muscle actin staining for activated stellate cells. Samples were collected, processed, stored and shipped in accordance with the procedure documented in a separate handling document. The Ishak fibrosis scoring system was used to score the fibrosis observed, with a minimum score of 0 and maximum score of 6 (where 0 = no fibrosis, 1 = expansion of some portal areas with or without septa, 2 = expansion of most portal areas with or without septa, 3 = expansion of most portal areas with occasional portal or portal bridging, 4 = expansion of portal areas with marked bridging \[portal-portal and/or portal-central\], 5 = marked bridging with occasional nodules \[incomplete cirrhosis\], 6 = cirrhosis, probable or definitive). The scores for liver biopsies were summarized based upon the availability of liver biopsy results.

Time frame:
Baseline and Week 144
Reported as:
Mean · Numerical score
Absolute Fibrosis Score (Ishak) in Liver Biopsy Samples at Baseline and at Week 144
Numerical scoreMaravirocPlacebo
Absolute Values at Baseline2.6 ± 2.301.5 ± 3.0
Absolute Values at Post-dose (or Week 144)2.2 ± 1.301.5 ± 3.0
SecondaryChange From Baseline in Fibrosis Score (Ishak) in Liver Biopsy Samples at Week 144

Samples were processed and sent to a central reader for scoring for fibrosis and other analyses such as Sirius red and α smooth muscle actin staining for activated stellate cells. Samples were collected, processed, stored and shipped in accordance with the procedure documented in a separate handling document. The Ishak fibrosis scoring system was used to score the fibrosis observed, with a minimum score of 0 and maximum score of 6 (where 0 = no fibrosis, 1 = expansion of some portal areas with or without septa, 2 = expansion of most portal areas with or without septa, 3 = expansion of most portal areas with occasional portal or portal bridging, 4 = expansion of portal areas with marked bridging \[portal-portal and/or portal-central\], 5 = marked bridging with occasional nodules \[incomplete cirrhosis\], 6 = cirrhosis, probable or definitive). The scores for liver biopsies were summarized based upon the availability of liver biopsy results.

Time frame:
Week 144
Reported as:
Median · Numerical score
Change From Baseline in Fibrosis Score (Ishak) in Liver Biopsy Samples at Week 144
Numerical scoreMaravirocPlacebo
Absolute Values at Baseline3 (0 to 6)0 (0 to 6)
Absolute Values at Post-dose (or Week 144)2 (1 to 4)0 (0 to 6)
Change from baseline in fibrosis score at Week 1440.0 (-2.0 to 1.0)0.0 (0.0 to 0.0)
SecondaryPercentage of Participants Who Were Hospitalized Due to Hepatic Disease Through Week 144

Healthcare resource utilization data was collected using the Healthcare Resource Utilization Questionnaire at all study visits except Screening and Baseline. Other components of healthcare resource utilization, including length of hospital stay, type of ward, associated investigative and therapeutic procedures and concomitant medications were captured from primary and secondary data sources.

Time frame:
144 Weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Hospitalized Due to Hepatic Disease Through Week 144
Percentage of participantsMaravirocPlacebo
Not Hospitalized71.470.1
Hospitalized due to Hepatic Disease at least once10.05.0
Hospitalized, but not due to Hepatic Disease95.095.0
SecondarySummary of Estimated Maraviroc PK Parameters

Week 4 and Week 48 clinic visits were scheduled such that a trough sample may be taken within a time window of 8-16 hours after the previous dose (Ctrough). Blood samples (4mL) were collected from all participants at the Week 4 and 48 visits.

Time frame:
Week 48
Reported as:
Median · ng/mL
Summary of Estimated Maraviroc PK Parameters
ng/mLMaraviroc 150 mgMaraviroc 300 mgMaraviroc 600 mg
Cavg262 (35 to 455)166 (72 to 187)309 (79 to 656)
Cmax496 (47 to 768)258 (162 to 528)915 (133 to 1734)
Cmin127.2 (21.6 to 280.5)61.3 (19.5 to 112.9)69.2 (17.3 to 250.9)
SecondaryExposure-response Relationship Between Change From Baseline in Liver Fibrosis Biomarkers Versus MVC Cavg at Week 48

The relationship between change from baseline in liver fibrosis biomarkers (AST, ALT, ALK, BIL, ELF and FSCN) versus MVC Cavg was analyzed using Bayesian methods. P-values were assessed for significance in the relationship between liver fibrosis biomarkers and MVC Cavg. P-value \<0.05 was regarded as significantly related.

Time frame:
Week 48
Reported as:
Number · p-value
Exposure-response Relationship Between Change From Baseline in Liver Fibrosis Biomarkers Versus MVC Cavg at Week 48
p-valueAspartate Transaminase (AST)Alanine Transaminase (ALT)Bilirubin (BIL)Enhanced Liver Fibrosis (ELF)Fibroscan (FSCN)Alkaline Phosphatase (ALK)
Exposure-response Relationship Between Change From Baseline in Liver Fibrosis Biomarkers Versus MVC Cavg at Week 480.8920.4400.7660.7950.0870.071

Adverse events

Collected over From the date of signing informed consent form up to 30 days after last dose of the study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maraviroc—22/70 (31.4%)63/70 (90%)
Placebo—19/67 (28.4%)62/67 (92.5%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventMaravirocPlacebo
BronchopneumoniaInfections and infestations3/700/67
SyncopeNervous system disorders2/700/67
Angina pectorisCardiac disorders0/701/67
Myocardial infarctionCardiac disorders0/701/67
Supraventricular tachycardiaCardiac disorders0/701/67
Adrenal insufficiencyEndocrine disorders0/701/67
CushingoidEndocrine disorders0/701/67
GastritisGastrointestinal disorders0/701/67
Chest painGeneral disorders0/701/67
CellulitisInfections and infestations0/701/67
Most frequent other events
Showing 10 of 342
Most frequent other events
EventMaravirocPlacebo
DiarrhoeaGastrointestinal disorders8/7012/67
Upper respiratory tract infectionInfections and infestations11/7011/67
Back painMusculoskeletal and connective tissue disorders4/7010/67
BronchitisInfections and infestations10/707/67
NauseaGastrointestinal disorders7/709/67
NasopharyngitisInfections and infestations9/706/67
CoughRespiratory, thoracic and mediastinal disorders9/702/67
SyphilisInfections and infestations3/708/67
ToothacheGastrointestinal disorders1/707/67
VomitingGastrointestinal disorders5/707/67

Baseline characteristics

A participant was included in the FAS if the participant had taken at least one dose of study drug.

Age, Customized
Age, Customized(Participants)MaravirocPlaceboTotal
<18 years000
18-44 years262046
45-64 years424789
≥65 years202
Sex: Female, Male
Sex: Female, Male(Participants)MaravirocPlaceboTotal
Female101020
Male6057117
08

Study locations

48 sites
  • The Office of Dr. Franco Antonio Felizarta, M.D.
    Bakersfield, California 93301, United States
  • AIDS Research Alliance
    Los Angeles, California 90015, United States
  • Alameda Health System - Highland Hospital
    Oakland, California 94602, United States
  • University of California Davis Research
    Sacramento, California 95811, United States
  • University of California
    Sacramento, California 95817, United States
  • University of California, San Francisco - Hepatitis/HIV Clinical Trials Group (HHCTG)
    San Francisco, California 94110, United States
  • University of California, San Francisco - Mt. Zion Hospital
    San Francisco, California 94115, United States
  • Community AIDS Resource Inc dba Care Resource
    Miami, Florida 33137, United States
  • University of South Florida Health - HIV Clinical Research Unit
    Tampa, Florida 33602, United States
  • Rowan Tree Medical, P.A.
    Wilton Manors, Florida 33305, United States
  • Georgia Regents Medical Center
    Augusta, Georgia 30912, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Mount Sinai Faculty Practice Associates
    New York, New York 10029, United States
  • The Mount Sinai Hospital
    New York, New York 10029, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • I.D. Consultants, P.A.
    Charlotte, North Carolina 28209, United States
  • Kaiser Permanente Sunnybrook Medical Office
    Clackamas, Oregon 97015, United States
  • Kaiser Permanente Northwest
    Portland, Oregon 97227, United States
  • Southwest Infectious Disease Clinical Research Inc.
    Dallas, Texas 75219, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75235, United States
  • University Health Care Center Downtown
    San Antonio, Texas 78207, United States
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Hopital de la Croix Rousse
    Lyon cedex 4, 69317, France
  • Centre Hospitalier Cochin Saint Vincent de Paul
    Paris CEDEX 14, 75679, France
  • Hopital Tenon, Service des Maladies Infectieuses
    Paris, 75020, France
  • EPIMED - Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH
    Berlin, 12157, Germany
  • Universitaetsklinikum Bonn, Immunologische Ambulanz HIV
    Bonn, 53127, Germany
  • ifi - Studien und Projekte GmbH
    Hamburg, 20099, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Klinikum der Universitaet zu Koeln
    Koeln, 50937, Germany
  • Ludwig-Maximilians-Universitaet
    Muenchen, 80336, Germany
  • Egyesített Szent István és Szent László Kórház Rendelőintézet
    Budapest, 1097, Hungary
  • EMC Instytut Medyczny S.A. Przychodnia przy ul. Lowieckiej
    Wroclaw, Dolnoslaskie 50-220, Poland
  • Wojewodzki Szpital Obserwacyjno - Zakazny im. Tadeusza Browicza w Bydgoszczy
    Bydgoszcz, 85-030, Poland
  • SPZOZ Wojewodzki Szpital Zakazny
    Warszawa, 01-201, Poland
  • Ararat Research Center
    Ponce, 00717-1567, Puerto Rico
  • Farmacia UPR-CTU
    San Juan, 00935, Puerto Rico
  • University of Puerto Rico - School of Medicine
    San Juan, 00935, Puerto Rico
  • Hospital Universitari Vall dHebron
    Barcelona, 08035, Spain
  • Hospital Reina Sofia Hospital Provincial
    Cordoba, 14004, Spain
  • Hospital Carlos Iii
    Madrid, 28029, Spain
  • Hospital Nuestra Señora de Valme
    Sevilla, 41014, Spain
  • Consorcio Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • Harrison Wing Research Office, Guys and St. Thomas NHS Foundation Trust
    London, SE1 7EH, United Kingdom
  • St Stephen's AIDS Trust
    London, SW10 9NH, United Kingdom
09

References and documents

Publications

  • Rockstroh JK, Plonski F, Bansal M, Fatkenheuer G, Small CB, Asmuth DM, Pialoux G, Zhang-Roper R, Wang R, Pineda JA, Heera J. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. Antivir Ther. 2017;22(3):263-269. doi: 10.3851/IMP3116. Epub 2016 Dec 7. PubMed 27924779 ↗
  • Rockstroh JK, Soriano V, Plonski F, Bansal M, Fatkenheuer G, Small CB, Asmuth DM, Pialoux G, Mukwaya G, Jagannatha S, Heera J, Pineda JA. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. HIV Clin Trials. 2015 Mar-Apr;16(2):72-80. doi: 10.1179/1528433614Z.0000000011. Erratum In: HIV Clin Trials. 2015 Nov;16(6):236-8. PubMed 25923596 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Apr 2013, 23 months.

Results were first posted in Nov 2014, 1 year 6 months after primary completion.

Of 91 phase 4 interventional studies under HIV Infections, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2011
First posted
Apr 1, 2011
StartActual
May 18, 2011
Primary completionActual
Apr 23, 2013
CompletionActual
Mar 24, 2015
Results first posted
Nov 14, 2014
Last update
Dec 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01327547
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Apr 1, 2011
Start date
May 18, 2011
Primary completion
Apr 23, 2013
Completion
Mar 24, 2015
Results posted
Nov 14, 2014
Last update
Dec 6, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion